Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine (MAPSS) MAPSS

What's the purpose of this trial?

Multiple myeloma patients will receive a cancer vaccine, called TXSVN that has been derived from the bacteria Salmonella. TXSVN is a weakened form of a live vaccine strain of the Salmonella bacteria (also known as the CVD908ssb strain) that has been genetically modified in the laboratory to produce a protein known as Survivin that stimulates an immune response in the body to the Survivin tumor antigen.  The purpose of this study is to find the largest safe dose of TXSVN, to learn what the side effects are, and to see whether this therapy might help participants with multiple myeloma.

This is an upcoming trial that has not yet started accepting patients.


What will happen during the trial?

Additional Trial Information

Phase 1

Enrollment: 24 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Texas

Dan L. Duncan Comprehensive Cancer Center Baylor College of Medicine

Houston, TX

Not Yet Accepting

The Methodist Hospital Research Institute

Houston, TX

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message